Effective Management of Refractory Folliculitis Decalvans Using Secukinumab

Abstract

This case study reports the successful management of a refractory case of folliculitis decalvans in a 40-year-old female patient
using Secukinumab, an interleukin-17A (IL-17A) inhibitor. The patient had a 14-year history of the condition, which had proven
resistant to previous treatments, including topical Betamethasone scalp lotion, Ketoconazole shampoo, and Adalimumab. This
case highlights the potential efficacy of Secukinumab as a therapeutic option for folliculitis decalvans refractory to conventional
treatments.